This was also true in another dataset from patients with breast, colorectal, and lung cancer (GSE103512) [28], where mean KRAS/CCL2/IL1B expression was significantly higher in lung and colorectal cancer, which have higher KRAS mutation rates [4], compared with breast cancer (Figure 7b). This evidence concerns the gene CCL2 and lung cancer.